Vedanta Raises $106.5M to Advance New Class of C.diff Therapeutics

Vedanta Biosciences closed a $106.5 million funding round on Tuesday to support a pivotal Phase III study of its candidate VE303 for Clostridioides difficile (C.diff) infection.

In addition to the Phase III study, Vedanta stated it plans to use the funds to run a proof-of-concept Phase II trial studying VE202, its investigational treatment for ulcerative colitis.